TWA
PCVX icon

TCI Wealth Advisors’s Vaxcyte PCVX Stock Holding History

TCI Wealth Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-258
Closed -$9.67K – 1632
2023
Q1 		$9.67K Buy
258
+116
+82% +$4.92K ﹤0.01% 1108
2022
Q4 		$6.81K Buy
+142
New +$5.57K ﹤0.01% 1331
2022
Q2 		– Sell
-132
Closed -$3K – 2458
2022
Q1 		$3K Hold
132
– – ﹤0.01% 1902
2021
Q4 		$3K Hold
132
– – ﹤0.01% 2022
2021
Q3 		$3K Buy
+132
New +$3.2K ﹤0.01% 1986

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TCI Wealth Advisors's PCVX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Vaxcyte (PCVX) in Q2 2023, closing a stake of 258 shares — an estimated $9.67K sold.

TCI Wealth Advisors first reported a position in PCVX in Q3 2021 and held it in 5 quarters. The position peaked at $9.67K in Q1 2023. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Vaxcyte position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 258 Vaxcyte shares in Q2 2023, an estimated $9.67K.
  • TCI Wealth Advisors first reported a position in Vaxcyte in Q3 2021 and held it in 5 quarters.
  • TCI Wealth Advisors's Vaxcyte position peaked at $9.67K in Q1 2023.
  • 197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.